Literature DB >> 10974179

Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis.

P S Mueller1, W D Edwards, M A Gertz.   

Abstract

PURPOSE: Obstructive intramural coronary amyloidosis is an unusual complication of systemic amyloidosis. SUBJECTS AND METHODS: We review the characteristics of 11 patients seen at the Mayo Clinic (Rochester, Minnesota) from January 1, 1960, to June 1, 1999, with intramural cardiac amyloidosis diagnosed at autopsy or after examination of an explanted heart.
RESULTS: Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis was found in 11 patients (8 men, 3 women). The mean (+/-SD) age at the diagnosis of primary amyloidosis was 62 +/- 12 years. All patients had angina pectoris; angina was the presenting symptom of primary amyloidosis in 6 patients. Unstable coronary syndromes occurred in 7 patients and congestive heart failure in 8. New electrocardiographic abnormalities after the development of angina were common and included ischemic changes, bundle branch block, and dysrhythmias. Low voltage was seen in only 2 patients. All 7 patients who underwent coronary angiography had normal or clinically insignificant findings. Endomyocardial biopsy was performed on 4 patients; amyloid was found in 3 patients, none of whom had obstructive intramural coronary amyloidosis. The diagnosis of obstructive intramural coronary amyloidosis with associated myocardial injury was established only at autopsy or after examination of the explanted heart after cardiac transplantation. The mean time to death or cardiac transplantation after symptoms of cardiac ischemia developed was 18 +/- 20 months.
CONCLUSIONS: The diagnosis of ischemic heart disease resulting from obstructive intramural coronary amyloidosis is difficult to establish before death or cardiac transplantation. Although the condition has a poor prognosis, its accurate recognition may have therapeutic implications, because some patients may benefit from treatment, including systemic chemotherapy or cardiac transplantation.

Entities:  

Mesh:

Year:  2000        PMID: 10974179     DOI: 10.1016/s0002-9343(00)00471-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  21 in total

1.  Coexistence of cardiac amyloidosis with coronary artery disease and the challenges in medical management.

Authors:  Vasvi Singh; Alexander Tiemeier; Saurabh Malhotra
Journal:  J Nucl Cardiol       Date:  2019-02-20       Impact factor: 5.952

Review 2.  Cardiac amyloidosis: the heart of the matter.

Authors:  Federico Perfetto; Francesco Cappelli; Franco Bergesio; Gabriele Ciuti; Maria Cristina Porciani; Luigi Padeletti; Alberto Moggi Pignone
Journal:  Intern Emerg Med       Date:  2011-07-08       Impact factor: 3.397

3.  Troponins in cardiac amyloidosis: multipurpose markers.

Authors:  Federico Perfetto; Franco Bergesio; Michele Emdin; Francesco Cappelli
Journal:  Nat Rev Cardiol       Date:  2014-01-28       Impact factor: 32.419

Review 4.  Transthyretin Cardiac Amyloidosis.

Authors:  Anit K Mankad; Keyur B Shah
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

5.  A case of a senile systemic amyloidosis patient presenting with angina pectoris and dilated cardiomyopathy.

Authors:  Gu Hyun Kang; Dong Ryeol Ryu; Pil Sang Song; Young Bin Song; Joo-Yong Hahn; Seung-Hyuck Choi; Hyeon-Cheol Gwon
Journal:  Korean Circ J       Date:  2011-04-30       Impact factor: 3.243

6.  Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins.

Authors:  Raymond Q Migrino; Seth Truran; David D Gutterman; Daniel A Franco; Megan Bright; Brittany Schlundt; Mitchell Timmons; Angelica Motta; Shane A Phillips; Parameswaran Hari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-30       Impact factor: 4.733

7.  Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance.

Authors:  E Perugini; C Rapezzi; T Piva; O Leone; L Bacchi-Reggiani; L Riva; F Salvi; L Lovato; A Branzi; R Fattori
Journal:  Heart       Date:  2005-06-06       Impact factor: 5.994

8.  Angina with a normal coronary angiogram caused by amyloidosis.

Authors:  D C Whitaker; M F Tungekar; J E Dussek
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

9.  Protective role of clusterin in preserving endothelial function in AL amyloidosis.

Authors:  Daniel A Franco; Seth Truran; Camelia Burciu; David D Gutterman; Anthony Maltagliati; Volkmar Weissig; Parameswaran Hari; Raymond Q Migrino
Journal:  Atherosclerosis       Date:  2012-09-01       Impact factor: 5.162

10.  Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up.

Authors:  Raymond Q Migrino; Richard Christenson; Aniko Szabo; Megan Bright; Seth Truran; Parameswaran Hari
Journal:  BMC Med Phys       Date:  2009-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.